For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
10
views
0
references
 Top references
cited by
64
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      0
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dupilumab, the first biological drug to be approved for the treatment of moderate to severe atopic dermatitis in adolescents and adults, has shown good efficacy and safety in clinical trials.

          Related collections

          Author and article information

          Journal
          Journal ID (iso-abbrev): J Am Acad Dermatol
          Title: Journal of the American Academy of Dermatology
          Publisher: Elsevier BV
          ISSN (Electronic): 1097-6787
          ISSN (Print): 0190-9622
          Publication date (Electronic): Jan 2021
          Volume: 84
          Issue: 1
          Affiliations
          [1 ] Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Copenhagen Research Group for Inflammatory Skin (CORGIS), Herlev and Gentofte Hospital, Hellerup, Denmark. Electronic address: anne-sofie.halling-overgaard.01@regionh.dk.
          [2 ] Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Copenhagen Research Group for Inflammatory Skin (CORGIS), Herlev and Gentofte Hospital, Hellerup, Denmark.
          [3 ] Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia.
          [4 ] Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York.
          Article
          Publisher Item ID: S0190-9622(20)32442-7
          DOI: 10.1016/j.jaad.2020.08.051
          PubMed ID: 32822798
          SO-VID: f03f12e5-0113-4728-9a42-01368b628fdd
          History

          Keywords: real-world evidence,dupilumab,atopic dermatitis,registries,adverse events,efficacy
          Data availability:
          Keywords: real-world evidence, dupilumab, atopic dermatitis, registries, adverse events, efficacy

          Comments

          Comment on this article